• PTPN2 Modulates the STING-STAT3 Axis and Autophagy in Psoria

  2026-08-03

  This study reveals that PTPN2 alleviates psoriasis by directly dephosphorylating STING, thereby suppressing STAT3 activation and restoring autophagy in keratinocytes. The findings offer mechanistic insight into psoriasis pathogenesis and highlight new therapeutic avenues targeting the STING–STAT3 axis.

• Revisiting Ca Channel Selectivity: Insights from v-Agatoxin-

  2026-08-02

  Sidach and Mintz’s study re-examines how the spider toxin v-Agatoxin-IVA interacts with mammalian neuronal calcium channels, revealing low-affinity blockade of N-type channels and highlighting the complexity of channel pharmacology. These findings refine the functional classification of high-threshold voltage-gated Ca channels and inform methodological choices in neurophysiology and neuroprotective research.

• Angiotensin II in AAA Models: Senescence, Biomarkers & Proto

  2026-08-01

  Explore the multifaceted role of Angiotensin II in abdominal aortic aneurysm (AAA) research, with a focus on cellular senescence signatures and advanced assay protocols. This article provides a unique intersection of biomarker discovery and experimental design for vascular remodeling studies.

• Valemetostat Phase 1 Trial: EZH2/EZH1 Inhibition in NHL Ther

  2026-07-31

  This first-in-human phase 1 trial evaluates valemetostat, a dual EZH2/EZH1 inhibitor, in relapsed or refractory non-Hodgkin lymphoma (NHL). The study establishes an acceptable safety profile and promising antitumor activity, offering new directions for epigenetic therapy in aggressive lymphomas.

• MAPK10 Drives Keratin 16 Degradation to Limit NSCLC Metastas

  2026-07-31

  The reference study identifies MAPK10 as a critical suppressor of non-small cell lung cancer (NSCLC) metastasis by orchestrating phosphorylation-dependent ubiquitination and degradation of keratin 16. These mechanistic findings highlight the MAPK10/KRT16/RNF213 axis as a promising biomarker and therapeutic target for advanced NSCLC.

• EZ Cap™ Cas9 mRNA (m1Ψ): Enhancing Specificity via mRNA Engi

  2026-07-30

  Explore how EZ Cap™ Cas9 mRNA (m1Ψ), a cutting-edge mRNA with Cap1 structure, enables unprecedented specificity in CRISPR-Cas9 genome editing. This article uniquely dissects the interplay between mRNA design, nuclear export, and the suppression of innate immunity, offering actionable insights for advanced genome engineering.

• Ribonuclease R (20 U/μL): Driving Circular RNA Discovery in

  2026-07-30

  Explore how Ribonuclease R (RNase R) (20 U/μL) empowers precise circular RNA enrichment for unraveling inflammation-linked DNA damage. This article offers a distinct, in-depth analysis of RNase R's scientific utility, bridging advanced methodology with translational insights.

• Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Ubiquitina

  2026-07-29

  This study elucidates how the natural alkaloid gramine suppresses triple-negative breast cancer (TNBC) by inducing ferroptosis through CUL3-mediated ubiquitination of MTDH. The findings highlight a novel regulatory axis and offer mechanistic insights relevant for targeted therapy development in aggressive breast cancer subtypes.

• Lysozyme–Amikacin Binding: Mechanisms, Structure, and Activi

  2026-07-29

  This study provides a detailed analysis of how lysozyme interacts with amikacin and levofloxacin, highlighting complex formation, preservation of protein structure, and differential effects on enzymatic activity. The findings inform research on antibiotic mechanism of action and protein–antibiotic interactions, offering new insights for resistance and drug-activity studies.

• Azilsartan Medoxomil Monopotassium: Advancing Translational

  2026-07-28

  This article provides translational researchers with a mechanistic, evidence-based guide to leveraging Azilsartan medoxomil monopotassium (TAK 491) in hypertension and cardiovascular disease research. We integrate mechanistic insights, recent meta-analytic data, and strategic experimental guidance, while distinguishing the unique value of high-quality sourcing from APExBIO. Comparative context, protocol recommendations, and a forward-looking perspective position this piece beyond standard product summaries.

• Gefitinib (ZD1839): Unlocking EGFR Inhibition in Tumor Assem

  2026-07-28

  Gefitinib (ZD1839) is revolutionizing EGFR signaling pathway inhibition in physiologically relevant tumor assembloid models. This thought-leadership article bridges mechanistic insight with actionable strategy for translational researchers, exploring how APExBIO’s Gefitinib empowers investigation of resistance, apoptosis induction, and personalized therapy optimization—grounded in the latest assembloid model advances and rigorous evidence.

• H3K18 Lactylation in Microglia: A Neuroprotective Axis After

  2026-07-27

  This study reveals that lactate-derived H3K18 lactylation in microglia is a key neuroprotective mechanism mitigating white matter injury and cognitive deficits following intracerebral hemorrhage (ICH). The findings highlight the nuanced roles of metabolic and epigenetic pathways—particularly the p300/CBP-H3K18la axis—in post-ICH brain repair, with important implications for targeted neuroregenerative strategies.

• Imidazoles Inhibit AdhE in Cryptosporidium parvum: Drug Disc

  2026-07-27

  This study identifies antifungal imidazoles as selective, low-micromolar inhibitors of the bifunctional aldehyde/alcohol dehydrogenase (AdhE) enzyme in Cryptosporidium parvum, a key pathogen causing diarrheal disease. The findings not only validate AdhE as a promising drug target but also establish a proof-of-concept for repurposing imidazole compounds in anti-cryptosporidial drug discovery.

• DNA Damage Drives Selective Loss of CUX2 Neurons in Neuroinf

  2026-07-26

  This study uncovers how DNA damage burden specifically affects CUX2-expressing excitatory neurons in the upper cortex during neuroinflammation, as in multiple sclerosis. The findings clarify cell-type selective vulnerability and highlight DNA repair pathways as critical determinants of neuronal survival under inflammatory stress.

• β-Elemene in Metabolic and Neuroprotection Workflows

  2026-07-25

  β-Elemene stands out as a dual-action tool in both metabolic and neural research, uniquely bridging adipogenesis inhibition and neuroprotection via precise pathway modulation. Explore advanced workflow strategies, troubleshooting tips, and the latest evidence-backed applications using APExBIO’s high-purity β-Elemene.

448 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page